GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » Cyclically Adjusted PB Ratio

SILO (SILO Pharma) Cyclically Adjusted PB Ratio : 0.23 (As of May. 29, 2025)


View and export this data going back to 2012. Start your Free Trial

What is SILO Pharma Cyclically Adjusted PB Ratio?

As of today (2025-05-29), SILO Pharma's current share price is $0.4722. SILO Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $2.06. SILO Pharma's Cyclically Adjusted PB Ratio for today is 0.23.

The historical rank and industry rank for SILO Pharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

SILO' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.21   Med: 1.34   Max: 21.82
Current: 0.23

During the past years, SILO Pharma's highest Cyclically Adjusted PB Ratio was 21.82. The lowest was 0.21. And the median was 1.34.

SILO's Cyclically Adjusted PB Ratio is ranked better than
81.19% of 670 companies
in the Biotechnology industry
Industry Median: 1.485 vs SILO: 0.23

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

SILO Pharma's adjusted book value per share data for the three months ended in Mar. 2025 was $0.895. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.06 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


SILO Pharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for SILO Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SILO Pharma Cyclically Adjusted PB Ratio Chart

SILO Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.52 4.77 1.70 0.66 0.43

SILO Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.46 0.51 0.43 0.57

Competitive Comparison of SILO Pharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, SILO Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SILO Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SILO Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where SILO Pharma's Cyclically Adjusted PB Ratio falls into.


;
;

SILO Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

SILO Pharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.4722/2.06
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SILO Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, SILO Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.895/134.9266*134.9266
=0.895

Current CPI (Mar. 2025) = 134.9266.

SILO Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201506 2.435 100.684 3.263
201509 1.991 100.392 2.676
201512 1.936 99.792 2.618
201603 1.851 100.470 2.486
201606 1.418 101.688 1.881
201609 0.988 101.861 1.309
201612 0.845 101.863 1.119
201703 1.588 102.862 2.083
201706 1.512 103.349 1.974
201709 0.994 104.136 1.288
201712 1.201 104.011 1.558
201803 1.219 105.290 1.562
201806 0.903 106.317 1.146
201809 0.966 106.507 1.224
201812 0.870 105.998 1.107
201903 0.625 107.251 0.786
201906 0.220 108.070 0.275
201909 -0.215 108.329 -0.268
201912 -0.049 108.420 -0.061
202003 -0.555 108.902 -0.688
202006 1.385 108.767 1.718
202009 1.216 109.815 1.494
202012 0.752 109.897 0.923
202103 2.483 111.754 2.998
202106 1.909 114.631 2.247
202109 5.145 115.734 5.998
202112 4.593 117.630 5.268
202203 4.277 121.301 4.757
202206 3.961 125.017 4.275
202209 3.776 125.227 4.068
202212 3.274 125.222 3.528
202303 2.990 127.348 3.168
202306 2.668 128.729 2.796
202309 2.411 129.860 2.505
202312 2.126 129.419 2.216
202403 1.868 131.776 1.913
202406 1.601 132.554 1.630
202409 1.512 133.029 1.534
202412 1.123 133.157 1.138
202503 0.895 134.927 0.895

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SILO Pharma  (NAS:SILO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


SILO Pharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of SILO Pharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SILO Pharma Business Description

Industry
Traded in Other Exchanges
N/A
Address
677 N. Washington Boulevard, Sarasota, FL, USA, 34236
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
Executives
Eric Weisblum director, officer: President and CCO 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Daniel E. Ryweck officer: Chief Financial Officer 712 VISTA BLVD #305, WACONIA MN 55387
Jeff Pavell director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Kevin Munoz director 560 SYLVAN AVE, SUITE 3160, ENGLEWOOD CLIFF NJ 07632
Wayne Linsley director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Adam C Wasserman officer: Chief Financial Officer 1643 ROYAL GROVE WAY, WESTON FL 33327
Leonard M Schiller director
Joel Alan Stone, director 1772 SABAL PALM DR., BOCA RATON FL 33432
Parker Walter Van Eps director C/O PROSPECT ENERGY CORPORATION, 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Richard Brand director, officer: Chairman and CEO 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Whalehaven Capital Fund Ltd 10 percent owner P O BOX HM 1027, HAMILTON D0 HMDX
Vadim Mats officer: VP of Business Development 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Donald Ptalis director, officer: CFO 72 POND ROAD, WOODBURY NY 11797
Melvin Schlossberg director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 72 POND ROAD, WOODBURY NY 11797